Race Oncology Limited (RAONF)

OTCMKTS · Delayed Price · Currency is USD
1.220
0.00 (0.00%)
At close: Jul 11, 2024
-15.86%
Market Cap 152.49M
Revenue (ttm) 2.67M
Net Income (ttm) -9.22M
Shares Out n/a
EPS (ttm) -0.06
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 8,000
Open 1.220
Previous Close n/a
Day's Range 1.220 - 1.220
52-Week Range 0.830 - 1.220
Beta 1.74
Analysts n/a
Price Target n/a
Earnings Date Nov 26, 2024

About Race Oncology

Race Oncology Limited, a clinical stage biopharmaceutical company, focuses on addressing the unmet needs of cancer patients for damaging treatments. The company’s lead product is bisantrene, a small molecule chemotherapeutic that has a clinical history with demonstrated therapeutic benefits in adult and paediatric patients. It is advancing reformulated bisantrene (RC220) to address the unmet need of patients across various oncology indications with a clinical focus on anthracycline combination to deliver cardioprotection and enhanced anticancer... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2011
Country Australia
Stock Exchange OTCMKTS
Ticker Symbol RAONF
Full Company Profile

Financial Performance

In 2024, Race Oncology's revenue was 4.00 million, an increase of 27.73% compared to the previous year's 3.13 million. Losses were -13.82 million, 39.3% more than in 2023.

Financial numbers in AUD Financial Statements

News

There is no news available yet.